Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-ups
Thalys has hit the limit up for three consecutive trading days, while Sinocelltech, Microchip Biotech, Science Sun Pharm, Changchun High-tech, and Sinobioway Medicine have all risen over 5%. Huahai Pharmaceutical, Jolly, Hotgen, and others have also followed suit. In terms of news, the National Healthcare Security Administration and the National Health Commission recently jointly issued "Several Measures to Support the High-Quality Development of Innovative Drugs," proposing 16 measures in 5 areas, emphasizing full-chain support for the research and development, access, hospital use, and diversified payment of innovative drugs
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments